N/A
Completed N=27
Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?
Source: ClinicalTrials.gov NCT00360282 ↗Enrolled (actual)
27
Serious AEs
0.0%
Results posted
Dec 2014
Primary outcomePrimary: Change From Baseline in Motion Sickness to Post Vestibular Stimulus — 5.1; 9 units on a scale — p=0.007
Summary
The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Motion Sickness to Post Vestibular Stimulus |
5.1; 9 | 0.007 sig |
| SECONDARY Change From Baseline in Subjective Units of Distress to Post Vestibular Stimulus |
3; 2 | .549 |
Eligibility Criteria
Inclusion Criteria
- History of motion sickness
- Currently suffering from migraines with at least 2 episodes during the previous 12 months
- Previous use and tolerance to triptans
Exclusion Criteria
- Current tobacco user
- History of or current hypertension, cardiac disease, arrhythmia, hypercholesterolemia, hemiplegic/basilar migraine, stroke, diabetes, vascular disease or kidney disease
- Family history of early myocardial infarction (first-degree relative 20/40 O.U.
- Women who are pregnant or breastfeeding
Data sourced from ClinicalTrials.gov (NCT00360282). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.